A practical reference on related substances: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-19 and is reviewed periodically as new material appears.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
The beta decay of 3H to 3He releases an electron and an antineutrino, and about 18 keV of energy. This is a low-energy decay, so the radiation cannot permeate skin. Tritium is thus only hazardous if directly ingested or inhaled.
In December 2024, the Auditor General of Ontario questioned the financial prudence of the relocation. Contrary to the Ford government's business plan analysis, which projected $257 million in savings over 50 years, the AG found that relocation costs have already exceeded the anticipated savings, reaching approximately $400 million.In May 2025, the Canadian Architect magazine reported that draft versions of the structural engineering report by Rimkus Consulting that the Ontario government had relied on in deciding to close the centre, had originally recommended routine repairs and not closure, up until May 2024. This revelation was added to earlier reporting from Global News that Infrastructure Ontario had been in frequent communication with Rimkus in the leadup to the public release of the report in June 2024, and led the magazine to conclude that the language describing the consequences of not doing the routine repair that was later used to justify the closure had been inserted after political pressure. In February 2026, Ford unveiled the designs of the new building and announced that a contract had been awarded for its construction. It will cost an estimated $1 billion and will be smaller than the original facility, with a footprint of about 400,000 square feet. The Centre would also incorporate the Ontario Place pods as exhibit space and the Cinesphere. The proposed move has been controversial.
Hydrogen peroxide should be stored in a cool, dry, well-ventilated area and away from any flammable or combustible substances. It should be stored in a container composed of non-reactive materials such as stainless steel or glass (other materials including some plastics and aluminium alloys may also be suitable). As it breaks down quickly when exposed to light, it should be stored in an opaque container, and pharmaceutical formulations typically come in brown bottles that block light. Hydrogen peroxide, either in pure or diluted form, may pose several risks, the main one being that it forms explosive mixtures upon contact with organic compounds. Distillation of hydrogen peroxide at normal pressures is highly dangerous. It is corrosive, especially when concentrated, but even domestic-strength solutions may cause irritation to the eyes, mucous membranes, and skin. Swallowing hydrogen peroxide solutions is particularly dangerous, as decomposition in the stomach releases large quantities of gas (ten times the volume of a 3% solution), leading to internal bloating. Inhaling over 10% can cause severe pulmonary irritation. With a significant vapour pressure (1.2 kPa at 50 °C), hydrogen peroxide vapour is potentially hazardous. According to U.S. NIOSH, the immediately dangerous to life and health (IDLH) limit is only 75 ppm. The U.S. Occupational Safety and Health Administration (OSHA) has established a permissible exposure limit of 1.0 ppm calculated as an 8-hour time-weighted average (29 CFR 1910.1000, Table Z-1).
APICS, Founded in 1957 as American Production and Inventory Control Society and re-branded as The Association for Supply Chain Management in 2018, launched their CSCP (Certified Supply Chain Professional) programme in 2006. Three years after ISCEA's CSCM. Institute for Supply Management, Founded in 1915 as National Association of Purchasing Agents, launched their CPSM Certified Professional in Supply Management programme in 2008. Five years after ISCEA's CSCM. Council of Supply Chain Management Professionals, Founded in 1963 as Council of Logistics Management, launched their SCPro programme in 2011. Eight years after ISCEA's CSCM.
Sources: en.wikipedia.org
== Incumbents == Lord Lieutenant of Anglesey – Henry Paget Lord Lieutenant of Brecknockshire and Monmouthshire – Henry Somerset, 6th Duke of Beaufort Lord Lieutenant of Caernarvonshire – Thomas Bulkeley, 7th Viscount Bulkeley Lord Lieutenant of Cardiganshire – Thomas Johnes Lord Lieutenant of Carmarthenshire – John Vaughan (until 19 January); George Rice, 3rd Baron Dynevor (from 21 April) Lord Lieutenant of Denbighshire – Sir Watkin Williams-Wynn, 5th Baronet Lord Lieutenant of Flintshire – Robert Grosvenor, 1st Marquess of Westminster Lord Lieutenant of Glamorgan – John Stuart, 1st Marquess of Bute Lord Lieutenant of Merionethshire - Sir Watkin Williams-Wynn, 5th Baronet Lord Lieutenant of Montgomeryshire – Edward Clive, 1st Earl of Powis Lord Lieutenant of Pembrokeshire – Richard Philipps, 1st Baron Milford Lord Lieutenant of Radnorshire – George Rodney, 3rd Baron Rodney Bishop of Bangor – William Cleaver Bishop of Llandaff – Richard Watson Bishop of St Asaph – Samuel Horsley Bishop of St Davids – Thomas Burgess
==== Bailout regulator ==== The emergency breathing gas from the bailout cylinder passes through a conventional scuba first stage regulator at the cylinder valve, via a low-pressure hose, to the bailout block, where it is normally isolated by the bailout valve. When the diver needs to switch over to bailout gas they simply open the bailout valve and the gas is supplied to the helmet or mask. As the valve is normally closed, a leak in the first stage regulator seat will cause the interstage pressure to rise, and unless an overpressure relief valve is fitted to the first stage the hose may burst. Aftermarket overpressure valves are available which can be fitted into a standard low-pressure port of most first stages. If the interstage pressure for the bailout regulator is lower than the main supply pressure, the main supply will override the bailout gas, and continue to flow. This can be a problem if the diver switches to bailout because the main supply is contaminated. If, on the other hand, bailout pressure is higher than main supply pressure, the bailout gas will override the main gas supply if the valve is opened. This will result in the bailout gas being used up if the valve leaks. The diver should periodically check that bailout cylinder pressure is still sufficient for the rest of the dive, and abort the dive if it is not. For this reason the bailout regulator must be fitted with a submersible pressure gauge to which the diver can refer to check the pressure.
==== Proton abstraction ==== Proton abstraction is different from the three ionization methods mentioned above because negative ions (NI) are formed during the process rather than positive ions. (M-H)− ions are often produced in polar organics in the NI mode. The first three ionization mechanisms discussed above all have their analogues in NI-FD-MS. In field ionization, molecular anions (M− ̇ ) can be generated. Anion attachment can also lead to the formation of negative ions for some molecules, for example, (M + Cl)−. Thermal desorption usually produces anion (A−) and cluster ion (e.g. CA2−) for salts.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.